Allergan reported $4.3 billion in fourth quarter GAAP net revenues, a 12% increase over the previous year’s fourth quarter, according to a company press release. Full-year net revenues increased to $15.9 billion.
GAAP operating loss from continuing operations was $90.5 million in the fourth quarter and $5.9 billion for the year, which the company attributed to impairment charges and research and development costs.
Revenues for the eye care arm increased to $671.7 million in 2017’s fourth quarter compared with $660.1 million in 2016’s fourth quarter. Restasis net revenues increased 1.8% to $400.3 million, while revenues for Ozurdex went up 16.8% to $26.4 million. Glaucoma products had a slight decline in revenue, with Alphagan/Combigan remaining stable at $101.8 million and Lumigan/Ganfort revenues decreasing 5.9% to $80.9 million.
For 2017, eye care revenues increased 0.9% to $2.46 billion.
Revenues for the facial aesthetics group increased 14.1% in the fourth quarter, with Botox revenues increasing 14.5% to $228.4 million. For the full year, facial aesthetics revenues increased 11.1% to $1.36 billion.